BIOAGE LABS INC. O.N. Aktie

At the Citigroup Biopharma Summit, BioAge announced a realignment of its pipeline: the primary focus is now on eye diseases such as diabetic macular edema (Phase II with BGE-102 has started), as well as biomarker-driven indications and next‑generation target structures. The company continues to emphasize the potential of its NLRP3 inhibitor BGE-102 despite changed investor sentiment after the ZEUS failure, and expects DME data in the second half of 2026 and QUELL‑CV topline results by the end of 2025. BioAge reports cash and equivalents of $381 million (Q2 2025), financial runway through 2029, and remains on a growth path with its APJ program and partnerships. » Plus sur de.investing.com

BioAge Labs shares fell 51.9% in premarket trading after Novo Nordisk’s IL‑6 inhibitor ziltivekimab showed no reduced risk of major cardiovascular events versus placebo in the phase‑3 ZEUS trial. The result calls into question the underlying assumption that blocking upstream inflammatory pathways confers cardiovascular benefit and directly weakens the prospects for BioAge’s oral NLRP3 inhibitor BGE‑102 in the ongoing phase‑2 QUELL‑CV study. Investors have markedly downgraded the likelihood of a positive outcome for BGE‑102 after a well‑funded, thematically related program failed. » Plus sur de.investing.com

BioAge has dosed the first participant in a randomized, double-blind, placebo-controlled phase‑2 dose-finding study of the oral NLRP3 inhibitor BGE-102. The QUELL-CV study aims to determine the optimal dose for phase‑3 development in participants with increased cardiovascular risk; topline data are expected in the second half of 2026. BGE-102 was developed from a compound identified using HitGen’s DNA-Encoded-Library (DEL) technology platform; phase‑1 data showed a reduction in high-sensitivity CRP. The partnership between HitGen and BioAge began in 2021 and underscores the application of HitGen’s DEL platform. » Plus sur de.investing.com